Trials / Completed
CompletedNCT00725296
Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)
Remicade Therapy in Psoriatic Arthritis: Investigation of Real Life Regimen in Austria Over 9 Consecutive Infusions
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 178 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time interval of Remicade (Infliximab) infusions in psoriatic arthritis (PsA).
Detailed description
This study population was chosen from a non-probability sample.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Remicade (Infliximab) | Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians. |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2010-07-01
- Completion
- 2010-07-01
- First posted
- 2008-07-30
- Last updated
- 2015-11-05
- Results posted
- 2011-07-29
Source: ClinicalTrials.gov record NCT00725296. Inclusion in this directory is not an endorsement.